Turkish cross-sectional survEy of glycemic and other metabolic parameters in patients with type 2 diabetes in 2023: Comparison with 2018 nationwide data (TEMD-2 study)

Basit Öğe Kaydı
dc.authorid0000-0002-9309-7715
dc.authorid0000-0002-6866-2364
dc.authorid0000-0002-8041-8161
dc.authorid0000-0002-1089-623X
dc.authorid0000-0002-3033-0073
dc.authorid0000-0002-9013-5237
dc.authorid0000-0003-4867-3725
dc.authorid0000-0003-4510-6282
dc.authorid0000-0002-9637-6744
dc.authorid0000-0001-8613-1797
dc.contributor.authorSönmez, Alper
dc.contributor.authorHaymana, Cem
dc.contributor.authorDemirci, İbrahim
dc.contributor.authorÇetinarslan, Berrin
dc.contributor.authorGönen, Mustafa Sait
dc.contributor.authorAkbaş, Emin Murat
dc.contributor.authorYenidünya Yalın, Gülşah
dc.contributor.authorAvcı, Uğur
dc.contributor.authorTaşcı, İlker
dc.contributor.authorSalman, Serpil
dc.contributor.authorErsoy, Canan
dc.contributor.authorBayram, Fahri
dc.contributor.authorSatman, İlhan
dc.date.accessioned2026-07-25T13:22:39Z
dc.date.available2026-07-25T13:22:39Z
dc.date.issued2026
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractAim: Five years after the first “Turkish nationwide survEy of glycemic and other Metabolic parameters of patients with type 2 Diabetes” (TEMD-1), attainment of glycemic, arterial blood pressure (ABP), and LDL-cholesterol (LDL-C) goals was re-investigated in patients with type 2 diabetes mellitus (T2DM), with an additional focus on therapeutic inertia. Methods: This cross-sectional study consecutively enrolled patients from 70 tertiary endocrine centers across Türkiye (November 2022–January 2023). Metabolic targets were HbA1c <7% (<53 mmol/mol), home ABP <135/85 mmHg, and risk-stratified LDL-C <55, <70, or <100 mg/dL (<1.4, <1.8, or <2.6 mmol/L). Thera peutic inertia was defined as failure to intensify treatment at enrollment. Results: Among the 4956 participants (mean age: 58.9 ± 10.0 years, women: 59.8%), HbA1c, ABP, LDL-C and triple metabolic control target attainment rates were 36.7%, 71.1%, 8.7%, and 2.8%, respectively. Glycemic control rate was found lower than the previous survey (40.0% vs. 36.7%, p < 0.001), while LDL-C control rate improved (7.0% vs. 8.7%, p = 0.002). Patients with established cardiovascular disease (CVD) showed worse outcomes, with triple metabolic control rate of 1.6%. The rate of severely uncontrolled diabetes (HbA1c >9%/ 75 mmol/mol) was 23.6%. Therapeutic inertia was observed by 33.5%, persisting uniformly across subgroups. Younger age, male sex, longer diabetes duration, lower socioeconomic status, and microvascular complications were independently associated with poor glycemic control. Conclusions: Metabolic control remains suboptimal in Turkish T2DM patients, and one-third of patients with severe hyperglycemia showed therapeutic inertia. Systematic interventions and intensified strategies are ur gently needed to improve diabetes outcomes and treatment inertia (ClinicalTrials.gov number NCT06347445).
dc.description.sponsorshipThis study was funded exclusively by the Turkish Society of Endo crinology and Metabolism (TEMD). Bu çalışma tamamen Türk Endokrinoloji ve Metabolizma Derneği (TEMD) tarafından finanse edilmiştir.
dc.identifier.citationSönmez, A., Haymana, C., Demirci, İ., Çetinarslan, B., Gönen, M. S., Akbaş, E. M., Yenidünya Yalın, G., Avcı, U., Taşcı, İ., Salman, S., Ersoy, C., Bayram, F., & Satman, İ. (2026). Turkish cross-sectional survEy of glycemic and other metabolic parameters in patients with type 2 diabetes in 2023: Comparison with 2018 nationwide data (TEMD-2 study). Journal of Diabetes and its Complications, 40(9), pp. 1-11. https://doi.org/10.1016/j.jdiacomp.2026.109348
dc.identifier.doi10.1016/j.jdiacomp.2026.109348
dc.identifier.endpage11
dc.identifier.issn1056-8727
dc.identifier.issn1873-460X
dc.identifier.issue9
dc.identifier.pmidPMID: 42413349
dc.identifier.scopus2-s2.0-105044053756
dc.identifier.scopusqualityQ2
dc.identifier.startpage1
dc.identifier.urihttps://doi.org/10.1016/j.jdiacomp.2026.109348
dc.identifier.urihttps://hdl.handle.net/20.500.13055/1565
dc.identifier.volume40
dc.identifier.wosWOS:001821999800001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynak.otherSCI-E - Science Citation Index Expanded
dc.institutionauthorSalman, Serpil
dc.institutionauthorid0000-0003-4867-3725
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofJournal of Diabetes and its Complications
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectType 2 Diabetes Mellitus
dc.subjectHba1c
dc.subjectLDL-Cholesterol
dc.subjectArterial Blood Pressure
dc.subjectCardiovascular Risk Factors
dc.subjectTherapeutic Inertia
dc.subjectHealthcare Quality
dc.subjectTürkiye
dc.subjectDiabetes Management
dc.titleTurkish cross-sectional survEy of glycemic and other metabolic parameters in patients with type 2 diabetes in 2023: Comparison with 2018 nationwide data (TEMD-2 study)
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
Tam Metin / Full Text.pdf
Boyut:
1.39 MB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu